BioSpace News Archive

BioMidwest

New CAP Guideline Improves Testing, Care, for Patients with Diffuse Gliomas

A new evidence-based guideline published by the College of American Pathologists can help improve how pediatric and adult patients with the most common type of primary brain tumor, diffuse glioma, are diagnosed and managed.

February 17, 2022

·

3 min read

BioMidwest

Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 17, 2022

Athersys, Inc. announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on January 21, 2022, the Company made an inducement grant to Daniel Camardo, the newly-appointed Chief Executive Officer of Athersys.

February 17, 2022

·

2 min read

Business

Quidel Reports Fourth Quarter and Full Year 2021 Financial Results

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2021.

February 17, 2022

·

24 min read

Business

Ribon Therapeutics, a Clinical Stage Biotechnology Company Targeting Stress Support Pathways in Cancer and Inflammation, Announces CEO Transition for Its Next Phase of Growth

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that the Board of Directors has appointed Prakash Raman, Ph.D., as President, Chief Executive Officer and member of the Board of Directors.

February 17, 2022

·

5 min read

Business

Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress

Enveric Biosciences is working with the University of Calgary’s Hotchkiss Brain Institute (“HBI”) to establish a groundbreaking clinical trial of EVM-101 for the treatment of Cancer Related Distress (“CRD”).

February 17, 2022

·

7 min read

Business

Partner Therapeutics Announces Contract with U.S. Department of Defense for Advanced Development of Leukine® to Treat Sulfur Mustard Gas (HD) Exposure

Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of Defense (DoD) to fund development and regulatory activities to support an sBLA of Leukine.

February 17, 2022

·

8 min read

Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study

Apyx Medical Corporation Announces Peer-Reviewed Publication Featuring Results from the U.S. IDE Clinical Study Evaluating the Renuvion ® Dermal Handpiece Using Apyx’s Helium Plasma Technology for Dermal Resurfacing Procedures.

February 17, 2022

·

7 min read

Drug Development

Maze Therapeutics Announces Phase 1 Trial Initiation Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease

Maze Therapeutics today announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.

February 17, 2022

·

2 min read

Business

Oncology Pharma Expands on Feasibility Studies and Data

Oncology Pharma Inc. wants to expand on a previously announced press release that included results of formulations and data on licensed technology with NanoSmart Pharmaceuticals.

February 17, 2022

·

7 min read

Business

Alimera Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022, and Provide Corporate Update

Alimera Sciences, Inc. announces today that it will report fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, prior to the market open.

February 17, 2022

·

1 min read